Sigrid Therapeutics recently announced that it has successfully secured $4 million in an oversubscribed funding round. The funding from existing and new investors underlines the strong investor confidence in Sigrid’s innovative SiPore technology.
The funding will be instrumental in accelerating the commercialization of SiPore across diverse markets, including medical devices, food supplements, and veterinary and oral health. And SiPore21 (the company’s flagship product) is undergoing SHINE clinical trials as a natural, non-drug solution for prediabetes progression and weight control. Administered orally, SiPore21 utilizes a carefully engineered mesoporous silica mineral to prevent digestive enzymes from breaking down carbohydrates and fats, offering a promising alternative to pharmaceutical methods.
KEY QUOTES:
“This funding will propel our efforts in establishing key partnerships and driving SiPore® technology to market. We are thrilled to have the backing of our investors as we move closer to providing effective solutions for obesity and diabetes management.”
– Sana Alajmovic, Sigrid’s Co-Founder and CEO
“Sigrid’s continued success is evident from the launch of one of the world’s largest prediabetes trial, SHINE, to SiPore21’s medical device classification and the commercial traction in our oral health vertical. These accomplishments show the company is well on track to deliver on its exciting potential.”
– Mattias Ankarberg, Sigrid’s Chairman
“We’re pleased that Sigrid Therapeutics’ recent share offering was oversubscribed by an impressive 50%. In today’s challenging financial climate, this achievement underscores the company’s quality and potential. Amidst concerns about obesity and diabetes, the demand for effective, non-drug therapies is evident. This success mirrors investor confidence and Sigrid’s commitment to pioneering drug-free solutions.”
– Lars Molinder, financial adviser to Sigrid Therapeutics
